

Supplemental Information

**The Neuromodulator Adenosine Regulates
Oligodendrocyte Migration
at Motor Exit Point Transition Zones**

Laura Fontenas, Taylor G. Welsh, Melanie Piller, Patricia Coughenour, Avni V. Gandhi, David A. Prober, and Sarah Kucenas

Figure S1




Figure S1 Related to Figures 1&4. Blocking of vesicular release results in larval paralysis.

(A) Percentage of embryos that were mobile or paralyzed during dechorionation with forceps at 2 dpf. Analyzed by Chi-squared test; ***p<0.0001, n = 54 (WT), n = 57 (TeNT). (B) Percentage of fish with positive and negative startle responses at 3 dpf. Analyzed by Fisher's exact test; ***p<0.0001, n = 52 (WT), n = 53 (TeNT). (C) Brightfield images of 3 and 5 dpf WT and *adora2ab*^{-/-} siblings injected with TeNT mRNA at the one-cell stage. Note that in the 5 dpf larvae, neither WT nor *adora2ab* mutants have inflated swim bladders because of their inability to swim and get to the surface of the petri dish to gulp air in order to inflate their swim bladder. (D) Brightfield images of 3 dpf WT and *gpr126*^{-/-} siblings injected with TeNT mRNA at the one-cell stage. Scale bars (C&D), 0.5 mm.

Figure S2




Figure S2 Related to Figure 2. A2a AR specifically mediates OPC migration at the MEP TZ.

(A-D) Dose response curves for the general AR antagonist CGS-15943 and antagonists selective for A1 (CPT), A2b (MRS 1754), and A3 (MRS 1191). (E) Mean ± SEM dorsal olig2⁺ cells at 3 dpf in *olig2:dsred* larvae treated with DMSO (n = 11), CGS-21680 (n = 9), or adenosine (n = 4), p=0.23. (F-H) Numbers of peripheral OPCs in larvae treated with 10 μM SCH-58261 during various developmental stages. All data presented are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 compared to DMSO, n = 9-12 fish per condition.

Figure S3




Figure S3 Related to Figure 3. A2a antagonism does not affect spinal motor nerve development.

(A) In situ hybridization for *wif1* in 54 hpf larvae treated 36 to 54 hpf with DMSO or 1.25 μ M CGS-15943. Arrowheads denote MEP glia. SC, spinal cord; N, notochord. (B) Image of a 5 dpf larva treated from 30 hpf to 3 dpf with SCH-58261. Arrowhead marks a *nkx*⁺/*sox10*⁺ oligodendrocyte on the nerve, which is myelinating proximal segments of the nerve with *nkx*⁺/*sox10*⁺/MBP⁺ myelin (yellow brackets). A differentiated Schwann cell also myelinates a nerve segment with a *nkx*⁺/*sox10*⁺/MBP⁺ myelin sheath (red bracket). Scale bars, (A) 20 μ m, (B) 50 μ m.

Figure S4

CLUSTAL O(1.2.3) multiple sequence alignment

SP P29274 AA2AR_HUMAN	-MPIMGSS VYITV ELA I AVLAILGNVLVCWAVLNSNLQNV	TN YFVVSLAA DIAVGVL	59
TR Q29ST5 Q29ST5_DANRE	----MSSLV YIVL ELVIAVLAAGNVLVCWAC	LNSNLQSI TNF FVVS LA ADIAVGVL	56
TR Q29ST6 Q29ST6_DANRE	MLNNVFDVLYM ILELLIALS VLGNVLVCWAVGLNSNLQSI TNF FVVS LA ADIAVGVL	A	60
SP P29274 AA2AR_HUMAN	IPFAIT ISTGFCAACHGCLFIACFVLVLTQSSIF SLLAIAIDRYIAIRIPLRYNGLVTGT	119	
TR Q29ST5 Q29ST5_DANRE	IPFAVT ISIGFCSNFHGCLFIACFVLVLTQSSVF SLLAIAAVDRYIAIKIPLRYNSLVTGR	116	
TR Q29ST6 Q29ST6_DANRE	IPFSIV ISTGFC ANFYGCLFIACFVLVLTQSSIF SLLAIAIDRYIAIKIPLRYNSLVTGQ	120	
SP P29274 AA2AR_HUMAN	RAK GIIAI CWVL SFAIGLTPMLGWNNCGQPKEGKNHSQCGCEGQVACL FEDVVP MNYM VY	179	
TR Q29ST5 Q29ST5_DANRE	RAK GIIAV CWIL SVVIGLTPMF GWNTSI ----DAGTNSSCPQGMTECL FEKVVT MGY MVY	172	
TR Q29ST6 Q29ST6_DANRE	R ARGIIAI CWVL SVI IGLTPMLGW HKARL---QEGHNGTCPPGMMECL FE EVVVMDY MVY	177	
SP P29274 AA2AR_HUMAN	FNFFACVLVPLL MLGVYLRIFLAARRQLKQMESQPL-----PGE-RARSTLQKEVHA	231	
TR Q29ST5 Q29ST5_DANRE	FNFFGC ILIP LFAM LAIYT WIF TAARRQLRQMEOKLAHLQGHAHKEGSSS RSTLQKEVHA	232	
TR Q29ST6 Q29ST6_DANRE	FNFFACVLVPLL MLAIYL RIFMAARHQL KCIESKAI-----PCELKS RSTLQKEVHA	230	
SP P29274 AA2AR_HUMAN	AKSLAIIVGLFAL CWLPHIINCFT CPDCSHAP LWL MYLAI VLSHTNSVVNPFIYAYR	291	
TR Q29ST5 Q29ST5_DANRE	AKSLAIIVGLFAVC WLPHIINC CPQC DRPQDWV MYLAI ILSHANSVVNPFIYAYR	292	
TR Q29ST6 Q29ST6_DANRE	AKSLAIIVGLFAVC WLPHIINC CPCE CPALI MYLAI ILSHANSVVNPFIYAYR	290	
SP P29274 AA2AR_HUMAN	IREFRQTFRKI IRSHVLRQQEPFKAGTSARVLAAGHS--DGEQVSLRL NHG -----P	342	
TR Q29ST5 Q29ST5_DANRE	IRD FRQTFRRIIRRHF LWHE SLAIGNNSNGGMTASSAAVSVI TSCTMS NGYVMDAANPI	352	
TR Q29ST6 Q29ST6_DANRE	IREFRHTFRKIV RYHILGRREPLSCNGSTRTSTRT--S--VADSLRIKV NGL -----V	339	
SP P29274 AA2AR_HUMAN	PGVWANGSAPH-----PERRPNGYALGLVSGGSAQE--SQG--NTGLPDVELLSHE	389	
TR Q29ST5 Q29ST5_DANRE	PGMISCDNFTKELPAKIKPQEEFQDLGYSL---NGSLDH--SF--NANSTPIFSSHSRE	404	
TR Q29ST6 Q29ST6_DANRE	RELYAEQSSTTSSCESAEPGHTHRPVSTENSILDNQPIEISNSHRHTALRHPESPLTGNN	399	
SP P29274 AA2AR_HUMAN	LKGVCPEPPGLDDPLAQ DGAGVS -----	412	
TR Q29ST5 Q29ST5_DANRE	EVSSIRDH--VEITTVK DCSDF --THVQDRCLMPVRTSNSSGLAEVS	447	
TR Q29ST6 Q29ST6_DANRE	EGLACRKHAGLDIT--- DGKDLSSPLHIKS --ALYVQTAHCVELTEVS	442	

Conserved sequence

Transmembrane domain

Ligand binding domain

Q29ST5 = A2ab
Q29ST6 = A2aa

Figure S4 Related to Figure 4. A2a AR protein sequence homology.

Clustal Omega sequence alignment for human A2a (top), zebrafish A2ab (middle), and zebrafish A2aa (bottom). Conserved sequence is in blue text, transmembrane domains are denoted in yellow highlight and ligand binding domains are bolded, underlined text.

Figure S5

A Sequence of *adora2aa* mutation

GRCz10 8:30671779 A2aa protein sequence Wild type TALEN non-synonymous mutations	ATGGACTCTTTCTGTAG-----CGGGACTTGAGTTCACATGGGATGGCTT ATGGACCTCTTCTGTAGGCTGGAGCAGGGACTTGAGTTCACATGGGATGGCTT 30671727
--	---

```

MLNNVFDVLYMILELLIALLSVLGNVLVCWAVGLNSNLQSITNFFVVSLAVADIAVGVLAIPIFSIVISTGFCANFYGCLFIACFVLVLTQSSIFSLLAIA
MLNNVFDVLYMILELLIALLSVLGNVLVCWAVGLNSNLQSITNFFVVSLAVADIAVGVLAIPIFSIVISTGFCANFYGCLFIACFVLVLTQSSIFSLLAIA
IDRYIAIKIPLRYSNLVTGQRARGIIAICWVLSVIIGLTPMLGWHKARLQEGRHNGTCPPGMMECLFEEVVVMMDYMVYFNFFACVLVPLLLMAlIYLRI
IDRYIAIKIPLRYSNLVTGQRARGIIAICWVLSVIIGLTPMLGWHKARLQEGRHNGTCPPGMMECLFEEVVVMMDYMVYFNFFACVLVPLLMAlIYLRI
AARHQLKCIESKAIPCELKSRLQKEVHAAKSLAIIVGLFAVCWLPLHIINCFLFCPECERPPALIMYLAIILSHANSVNPFIYAYRIRERFRHTFRK
AARHQLKCIESKAIPCELKSRYRKRSMRNR*
IVRYHILGRREPLSCNGSTRTRTSVADSLRIKVNGLVRELYAEQSSTSSCESAEPGHTHRPVSTENSILDNQPIEISNSHRHTALRHPEPLTGNN
GLACRKHAGLDITDGKDLSSPLHIKSALYVQTAHCVELTEVS*

```

B




Figure S5 Related to Figure 4. Characterization of *adora2aa* mutant larvae.

(A) DNA sequence (top) and predicted protein sequence of *adora2aa*^{ct845} compared to WT.
(B) Brightfield images of 3 dpf WT and *adora2aa*^{-/-} larvae. (C) Mean ± SEM of peripheral OPCs per larvae for *adora2aa*^{+/+} and *adora2aa*^{-/-} larvae at 3 dpf. p=0.24, n = 20 (*adora2aa*^{+/+}), n = 26 (*adora2aa*^{-/-}). Scale bar, 0.5 mm.

Figure S6




Figure S6 Related to Figure 4. Knockdown of adora2ab, but not adora2aa, results in peripheral OPCs. (A) Mean ± SEM of peripheral OPCs in WT *olig2:dsred* embryos injected with vehicle, 1 ng/nl *adora2aa* MO1 or 1 ng/nl *adora2ab* MO1. n = 42 (WT), n = 11 (phenol red), n = 65 (*adora2aa* MO1) and n = 42 (*adora2ab* MO1). ***p<0.0001 *adora2ab* MO1 compared to uninjected. (B) Mean ± SEM of peripheral OPCs at 3 dpf in *olig2:dsred;adora2aa-/-* larvae injected with *adora2ab* MO1. n = 44 (uninjected), n = 30 (phenol red) and n = 84 (*adora2ab* MO1). ***p<0.0001 compared to uninjected. (C) Brightfield images of 3 dpf WT, *adora2aa* and *adora2ab* morphant larvae. (D) Mean ± SEM of peripheral OPCs at 3 dpf in *olig2:dsred;adora2aa-/-;adora2ab-/-* larvae. p=0.75, n = 2 (*adora2aa*^{+/+}; *adora2ab*^{+/+}), n = 11 (*adora2aa*^{+/+}; *adora2ab*^{-/-}), n = 6 (*adora2aa*^{+/+}; *adora2ab*^{-/-}), n = 8 (*adora2aa*^{-/-}; *adora2ab*^{+/+}), n = 20 (*adora2aa*^{-/-}; *adora2ab*^{-/-}), n = 4 (*adora2aa*^{+/+}; *adora2ab*^{-/-}), n = 3 (*adora2aa*^{-/-}; *adora2ab*^{+/+}), n = 6 (*adora2aa*^{-/-}; *adora2ab*^{-/-}) and n = 4 (*adora2aa*^{-/-}; *adora2ab*^{-/-}). Scale bar, 0.5 mm. (E) Mean ± SEM of peripheral OPCs at 3 dpf in *olig2:dsred;adora2ab-/-* and *adora2ab*^{+/+} larvae injected with 1ng/nl *adora2ab* MO at the one-cell stage. *p = 0.03, n = 20 (*adora2ab*^{+/+}); n = 13 (*adora2ab*^{-/-}).

Figure S7




Figure S7 Related to Figure 5. Modulation of neuronal activity affects OPC migration.

(A) A2a antibody expression in motor axons (solid arrowheads) and sensory axons (open arrowheads) in a 72 hpf *sox10:eos* larva. (B) Example traces for calcium responses in individual GCaMP-expressing neurons in larvae treated with DMSO or SCH-58261. (C) Mean \pm SEM peripheral OPCs per larvae at 3 dpf after treatment with carbenoxolone from 36 hpf to 3 dpf. n = 8 (0 μM), n = 9 (1.25 μM), n = 10 (2.5 μM), n = 9 (5 μM), n = 5 (10 μM), n = 9 (20 μM) and n = 1 (40 μM). 40 μM dose was excluded from statistical analysis. *p<0.05, **p<0.001 compared to 0 μM .

Table S1 Related to Star Methods. Transgenes used in this study, with abbreviations and descriptions of structures labeled.

Transgene name	Abbreviation	Description
<i>Tg(sox10(4.9):eos)^{w9}</i>	<i>sox10: eos</i>	Photoconvertible Eos protein expressed by OPCs, Schwann cells, MEP glia and some interneurons
<i>Tg(sox10(4.9):nls-eos)^{w18}</i>	<i>sox10:nls-eos</i>	Photoconvertible Eos protein expressed in the nucleus of Sox10-expressing cells
<i>Tg(olig2:egfp)^{vu12}</i>	<i>olig2:egfp</i>	GFP expressed by motor neurons and axons, OPCs, MEP glia and some interneurons
<i>Tg(olig2:dsred2)^{vu19}</i>	<i>olig2:dsred</i>	DsRed2 expressed by motor neurons and axons, OPCs, MEP glia and some interneurons
<i>Tg(nkx2.2a:megfp)^{vu17}</i>	<i>nkx2.2a:megfp</i>	Membrane-tethered GFP expressed by perineurial glia and myelinating oligodendrocytes
<i>Tg(mbp:egfp-CAAX)^{ue2}</i>	<i>mbp:megfp</i>	Membrane-tethered GFP expressed by myelinating glia
<i>Tg(neurod:gal4)^{uva22}</i>	<i>neurod:gal4</i>	Gal4 expressed by neurons